Evidence map›Paper›PMID 32793278›Full record

ArticleFrontiers in genetics2020

Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening.

Andrei Sorop, Razvan Iacob, Speranta Iacob, Diana Constantinescu, Leona Chitoiu, Tudor Emanuel Fertig, Anca Dinischiotu, Mihaela Chivu-Economescu, Nicolae Bacalbasa, Lorand Savu and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Diagnostic value of exosomes in patients with liver cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. [Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Andrei SoropCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Razvan IacobCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Speranta IacobCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Diana ConstantinescuCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Leona ChitoiuUltrastructural Pathology Laboratory, Victor Babeş National Institute, Bucharest, Romania.
Tudor Emanuel Fertig"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Anca DinischiotuFaculty of Biology, University of Bucharest, Bucharest, Romania.
Mihaela Chivu-EconomescuFaculty of Biology, University of Bucharest, Bucharest, Romania.
Nicolae BacalbasaCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Lorand SavuCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Liliana GheorgheCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Simona DimaCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Irinel PopescuCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Institutul Clinic Fundeni · ROCarol Davila University of Medicine and Pharmacy · ROInstitutul National Victor Babes · ROUniversity of Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiquid biopsy using circulating microvesicles and exosomes is emerging as a new diagnostic tool that could improve hepatocellular carcinoma (HCC) early diagnosis and screening protocols. Our study aimed to investigate the utility of plasma exosomal miR-21-5p and miR-92-3p for HCC diagnosis during screening protocols.

methodsThe study group included 106 subjects: 48 patients diagnosed with HCC during screening, who underwent a potentially curative treatment (surgical resection or liver transplantation), 38 patients with liver cirrhosis (LC) on the waiting list for liver transplantation, and 20 healthy volunteers. The exosomes were isolated by precipitation with a reagent based on polyethylene glycol and were characterized based on morphological aspects (i.e., diameter); molecular weight; CD63, CD9, and CD81 protein markers; and exosomal miR-21-5p and miR-92a-3p expression levels.

resultsWe first demonstrate that the exosome population isolated with the commercially available Total Exosome Isolation kit respects the same size ranging, morphological, and protein expression aspects compared to the traditional ultracentrifugation technique. The analysis of the expression profile indicates that miR-21-5p was upregulated (

conclusionTogether with serum AFP, plasma exosomal miR-21-5p and miR-92a-3p could be used as potential biomarkers for HCC diagnosis in patients with LC subjected to screening and surveillance.

Indexed as

exosomeshepatocellular carcinomamicroRNAscreeningserum biomarkers

Identifiers

PMID32793278
PMCPMC7391066
OpenAlexW3045366469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.